Virax Biolabs Group Ltd cash flow statement VRAX
In fiscal 2025, which ended Mar 31, 2025, Virax Biolabs Group Ltd used $4.6 million of cash from operations, up 26.9% from the year before. It spent $603,890 on capital expenditures. Free cash flow was negative, at -$5.2 million.
USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.
| Line |
FY 2025
Mar 31, 2025
|
FY 2024
Mar 31, 2024
|
FY 2023
Mar 31, 2023
|
FY 2022
Mar 31, 2022
|
|---|---|---|---|---|
| Operating | ||||
| Depreciation and amortization |
0
+385.9%
|
0
|
—
|
—
|
| Operating cash flow |
-5
+26.9%
|
-6
-49.5%
|
-4
-416.6%
|
-1
|
| Investing | ||||
| Capital expenditures |
1
-36.6%
|
1
|
—
|
—
|
| Investing cash flow |
-1
+48.1%
|
-1
-552.7%
|
-0
|
—
|
| Financing | ||||
| Financing cash flow |
6
+252.3%
|
2
-88.0%
|
14
+1583.3%
|
1
|
| Change in cash | ||||
| Net change in cash |
1
+111.1%
|
-6
-161.8%
|
9
+225553.7%
|
0
|
| Free cash flow |
-5
+28.2%
|
-7
|
—
|
—
|
| Per share | ||||
| Free cash flow per share |
-1.39
+61.4%
|
-3.59
|
—
|
—
|
| Ratios | ||||
| Free cash flow margin |
-81,621.64%
|
-4,602.71%
|
—
|
—
|
| Capital expenditures to revenue |
9,538.62%
|
608.94%
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- VRAX (Nasdaq)
- Fiscal year ends
- March 31
- Incorporated in
- Cayman Islands
- Headquarters
- Lanarkshire, United Kingdom
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1885827
- Former names
- Virax Biolabs (Cayman) Ltd (until Dec 27, 2021)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.